New Nature Neuroscience data shows MCU inhibition blocks drug reward without touching natural reward circuits, a mechanistic ...

Fortrea's $45M acquisition of Worldwide Clinical Trials' early-phase division reshapes Phase I site networks and vendor ...

Myriad bioscaffolds demonstrated a 0.7% deep infection rate in soft tissue reconstruction across 411 patients, significantly ...

Tekton Research sites enrolled 60 participants in Phase 2 obesity trial, tripling their combined enrollment goal and ...

Clover's RSV-hMPV vaccine produced 6-to-9-fold antibody rises in Phase 2, with no immune interference and strong safety.

Rather than stimulating native soluble guanylate cyclase the way sGC stimulators do, mosliciguat directly activates the ...

Canada's drug agency recommends conditional reimbursement for palopegteriparatide in hypoparathyroidism, pending price ...

Signant Health and Lothar Medical plan integrated respiratory trial device combining spirometry, oscillometry, and FeNO ...

FDA guidance expands cancer trial eligibility to include patients with ECOG PS 2, reshaping enrollment models and operational ...

Intellia secures $400M credit facility to fund the NTLA-2002 HAE trial through completion, avoiding shareholder dilution from ...

Tarsus Pharmaceuticals acquires gildeuretinol for Stargardt disease, an oral drug in Phase 3 development with FDA ...

Inhibrx releases Phase 2 primary endpoint data for INBRX-106 in head and neck cancer, testing hexavalent OX40 agonist plus ...